The Nycomed Amersham Imaging agent Myoview may soon be used to assess coronary artery disease in patients who are unable to physically exert themselves, according to the Princeton, NJ, company.
The Food and Drug Administration has issued an approvable letter for use of the technetium Tc-99m preparation kit with pharmacological stress agents. The company submitted the application to the FDA 10 months ago and will now work toward market approval, said Dr. John Padfield, CEO of Nycomed Amersham Imaging. Myoview is already in use for cardiac perfusion imaging.
By AuntMinnie.com staff writers
February 29, 2000
Copyright © 2000 AuntMinnie.com